GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sienna Biopharmaceuticals Inc (OTCPK:SNNAQ) » Definitions » Capex-to-Operating-Cash-Flow

Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Capex-to-Operating-Cash-Flow : 0.00 (As of Sep. 2019)


View and export this data going back to 2017. Start your Free Trial

What is Sienna Biopharmaceuticals Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

Sienna Biopharmaceuticals's Capital Expenditure for the three months ended in Sep. 2019 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Sep. 2019 was $-17.84 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


Sienna Biopharmaceuticals Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for Sienna Biopharmaceuticals's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sienna Biopharmaceuticals Capex-to-Operating-Cash-Flow Chart

Sienna Biopharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18
Capex-to-Operating-Cash-Flow
- - - -

Sienna Biopharmaceuticals Quarterly Data
Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Sienna Biopharmaceuticals's Capex-to-Operating-Cash-Flow

For the Biotechnology subindustry, Sienna Biopharmaceuticals's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sienna Biopharmaceuticals's Capex-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sienna Biopharmaceuticals's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Sienna Biopharmaceuticals's Capex-to-Operating-Cash-Flow falls into.



Sienna Biopharmaceuticals Capex-to-Operating-Cash-Flow Calculation

Sienna Biopharmaceuticals's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2018 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-0.039) / -61.693
=N/A

Sienna Biopharmaceuticals's Capex-to-Operating-Cash-Flow for the quarter that ended in Sep. 2019 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -17.844
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sienna Biopharmaceuticals  (OTCPK:SNNAQ) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


Sienna Biopharmaceuticals Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Sienna Biopharmaceuticals's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Sienna Biopharmaceuticals (Sienna Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
30699 Russell Ranch Road, Suite 140, Westlake Village, CA, USA, 91362
Sienna Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development, and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. The objective is to develop multi-asset pipeline of topical therapies that enhance the health, appearance, and quality of life of dermatology patients. The product portfolio includes SNA-120, SNA-125, and SNA-001.
Executives
Alexander Azoy officer: Chief Financial Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Timothy K. Andrews officer: General Counsel & Secretary 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Iii Frederick Beddingfield director, officer: President & CEO C/O KYTHERA BIOPHARMACEUTICALS, INC. 27200 WEST AGOURA ROAD, SUITE 200 CALABASAS CA 91301
Paul F. Lizzul officer: Chief Medical Officer 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Diane Stroehmann officer: See Remarks 30699 RUSSELL RANCH ROAD SUITE 140 WESTLAKE VILLAGE CA 91362
Dennis M Fenton director
Todd Harris director 30699 RUSSELL RANCH ROAD, SUITE 140, WESTLAKE VILLAGE CA 91362
Kristina Burow director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Robert J More director 680 S CACHE STREET, SUITE 100, BOX 10820, JACKSON WY 83001
James M. Hindman director 2525 DUPONT DRIVE, IRVINE CA 92612
Keith R Leonard director ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Arch Venture Partners Viii, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund Viii Overage, L.p. 10 percent owner C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Fund X Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X Overage, L.p. 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631